https://www.selleckchem.com/btk.html
Background Platelet refractoriness remains a challenging clinical dilemma although significant advancements have been made in identifying human leukocyte antigen (HLA) matched or HLA compatible units. Antiplatelet antibodies are the major risk factor for immune-mediated platelet refractoriness, yet the role of antibody-initiated complement-mediated platelet destruction remains poorly understood. Study design and methods Human complement-mediated opsonization and killing of platelets was assayed ex vivo using antibody-sensitized human platelets incub
Aimer
Commentaire
Partagez
